Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell–mediated lysis of myeloma
Open Access
- 1 February 2008
- journal article
- Published by American Society of Hematology in Blood
- Vol. 111 (3) , 1309-1317
- https://doi.org/10.1182/blood-2007-03-078535
Abstract
Human leukocyte antigen class I molecules expressed by tumor cells play a central role in the regulation of natural killer (NK) cell–mediated immuneKeywords
This publication has 55 references indexed in Scilit:
- Bortezomib enhances dendritic cell (DC)–mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implicationsBlood, 2007
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1Blood, 2006
- Bortezomib and Depsipeptide Sensitize Tumors to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand: A Novel Method to Potentiate Natural Killer Cell Tumor CytotoxicityCancer Research, 2006
- Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor ILeukemia, 2005
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignanciesCell Death & Differentiation, 2004
- p46, a Novel Natural Killer Cell–specific Surface Molecule That Mediates Cell ActivationThe Journal of Experimental Medicine, 1997
- Peptide antigen production by the proteasome: complexity provides efficiencyImmunology Today, 1996
- Thermal Stability Comparison of Purified Empty and Peptide-Filled Forms of a Class I MHC MoleculeScience, 1992
- Isolation of an endogenously processed immunodominant viral peptide from the class I H–2Kb moleculeNature, 1990